CLAIMS

1. Use of a composition for treating withdrawal symptoms and pain associated with the withdrawal of anti-depressants, selective serotonin inhibitors (SSRI), or other neurological agents in a subject comprising:

N-2-hydroxy-ethyl-piperazine-N'-2-ethane sulfonic acid (HEPES) and derivatives thereof dissolved in sterile water, buffer, saline or other pharmaceutically acceptable carriers in an amount sufficient to treat withdrawal symptoms and pain associated with the withdrawal of following treatment with one or more anti-depressants, one or more selective serotonin inhibitors (SSRI), or other neurological agents; and

one or more optional excipients, diluents, extended or controlled release agents, coloring agents, preservatives or any combinations thereof.

2. The use of claim 1, wherein the HEPES is dissolved in sterile water for injection for oral, subcutaneous, parenteral, intravenous, peritoneal, or intramuscular administration.

3. The use of claim 1, wherein the composition is administered once daily on a body weight basis at 10-100 mg/kg.

4. The use of claim 1, wherein the anti-depressants are selected from the group consisting of benzodiazepines, SSRIs, Serotonin-norepinephrine reuptake inhibitors (SNRIs), Noradrenergic and specific serotonergic antidepressants (NaSSAs), Norepinephrine (noradrenaline) reuptake inhibitors (NRIs), Norepinephrine-dopamine reuptake inhibitors (NDRIs), Selective serotonin reuptake enhancers (SSREs), Melatonergic agonists, Tricyclic antidepressants (TCAs), and Monoamine oxidase inhibitor (MAOIs).

5. The use of claim 1, wherein the SSRIs comprise citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, zimelidine or any combinations thereof.

CLAIMS

1. Use of N-2-hydroxy-ethyl-piperazine-N'-2-ethane sulfonic acid (HEPES) or a derivative thereof dissolved in sterile water, buffer, saline or other pharmaceutically acceptable carriers; and

one or more optional excipients, diluents, extended or controlled release agents, coloring agents, preservatives or any combinations thereof

in the manufacture of a medicament for the treatment of withdrawal symptoms and pain associated with withdrawal of anti-depressants, selective serotonin inhibitors (SSRI) wherein the symptoms are due to demyelination.

2. The use of claim 1, wherein the HEPES is dissolved in sterile water for injection for oral, subcutaneous, parenteral, intravenous, peritoneal, or intramuscular administration.

3. The use of claim 1, wherein the once daily dose is based on a body weight at 10-100 mg/kg.

4. The use of claim 1, wherein the anti-depressants are selected from the group consisting of benzodiazepines, SSRIs, Serotonin-norepinephrine reuptake inhibitors (SNRIs), Noradrenergic and specific serotonergic antidepressants (NaSSAs), Norepinephrine (noradrenaline) reuptake inhibitors (NRIs), Norepinephrine-dopamine reuptake inhibitors (NDRIs), Selective serotonin reuptake enhancers (SSREs), Melatonergic agonists, Tricyclic antidepressants (TCAs), and Monoamine oxidase inhibitor (MAOIs).

5. The use of claim 1, wherein the SSRIs comprise citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, zimelidine or any combinations thereof.